Monoclonal antibodies

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Retrieved on: 
Tuesday, July 27, 2021
Medical specialties, Clinical medicine, Immunology, Medicine, Biotechnology, Monoclonal antibodies, Antibody-drug conjugate, Immune system, Antibody

Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).

Key Points: 
  • Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).
  • The antibodies generated by Glycotope are designed to deliver very high tumor selectivity.
  • Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • Glycotope has to date discovered in excess of 130 GlycoTargets with antibodies against several of these targets currently under development.

Byondis and Glycotope Enter Platform Access Agreement for Discovery and Development of Antibodies Against Novel GlycoTargets

Retrieved on: 
Tuesday, July 27, 2021
Medical specialties, Clinical medicine, Immunology, Medicine, Biotechnology, Monoclonal antibodies, Antibody-drug conjugate, Immune system, Antibody

Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).

Key Points: 
  • Under the terms of the platform access agreement, Byondis has gained exclusive rights to evaluate and develop antibodies against selected novel GlycoTargets, with the option to in-license these antibodies for development as antibody-drug conjugates (ADCs).
  • The antibodies generated by Glycotope are designed to deliver very high tumor selectivity.
  • Glycotope is a biotechnology company utilizing a proprietary technology platform to develop uniquely tumor-specific monoclonal antibodies.
  • Glycotope has to date discovered in excess of 130 GlycoTargets with antibodies against several of these targets currently under development.

Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Alzheimer's disease, Amyloidosis, Monoclonal antibodies, Biology, Life sciences, Aducanumab, Amyloid beta, Accelerated approval, Indication, Amyloid, Biogen

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Key Points: 
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM.
  • Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).
  • Several of these relationships were not apparent in ENGAGE, in which a clinical treatment effect of aducanumab was not observed.

F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors

Retrieved on: 
Monday, July 26, 2021
Drugs, Orphan drugs, Breakthrough therapy, Health sciences, Health care, Atezolizumab, Clusters of differentiation, PD-L1, Monoclonal antibodies, Cancer immunotherapy

The ongoing multicenter clinical trial ( NCT04096638 ) is evaluating the safety and efficacy of intravenously (IV) administered SB 11285 alone and in combination with the anti-PD-L1 monoclonal antibody, atezolizumab, in patients with advanced solid tumors.

Key Points: 
  • The ongoing multicenter clinical trial ( NCT04096638 ) is evaluating the safety and efficacy of intravenously (IV) administered SB 11285 alone and in combination with the anti-PD-L1 monoclonal antibody, atezolizumab, in patients with advanced solid tumors.
  • In clinical trials, the first generation of these compounds were typically injected intratumorally in patients with solid cancers.
  • F-stars SB 11285 is differentiated from the first generation of STING agonists, as it is delivered systemically, enabling access to hard-to-reach tumors.
  • Additionally, SB 11285 may facilitate migration of newly activated immune cells from the periphery into the tumor site.

Biogen to Present Data from ADUHELM and Alzheimer’s Disease Portfolio at 2021 Alzheimer’s Association International Conference

Retrieved on: 
Friday, July 23, 2021
Branches of biology, Biology, Medicine, Monoclonal antibodies, Treatment of Alzheimer's disease, Alzheimer's disease, Cognitive disorders, Psychiatric diagnosis, Aducanumab, Biomarker, Disease

There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.

Key Points: 
  • There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied.
  • The companys contributions to the congress include four presentations on ADUHELM data and a total of 11 abstracts.
  • The company will also lead a late-breaking presentation on the design of the real-world observational Phase 4 study in Alzheimers disease, a prospective registry of ADUHELM, called International Collaboration for Real-World Evidence in Alzheimers Disease (ICARE AD-US).
  • Poster presentation: Reduction in Biomarkers of Alzheimers Disease Pathophysiology Following Treatment with Aducanumab Were Associated with Slowing Clinical Decline virtual poster #57499.

MacroGenics Announces Date of Second Quarter 2021 Financial Results Conference Call

Retrieved on: 
Thursday, July 22, 2021
Life sciences, Biotechnology, Health sciences, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Conference call, Monoclonal antibodies

The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 7983402.

Key Points: 
  • The conference call can be accessed by dialing (877) 303-6253 (domestic) or (973) 409-9610 (international) five minutes prior to the start of the call and providing the Conference ID# 7983402.
  • The listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at http://ir.macrogenics.com/events.cfm .
  • MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
  • MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

US Wet Age-Related Macular Degeneration Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Health, Optical, Macular degeneration, Senescence, Organ systems, Branches of biology, Stem cells, Monoclonal antibodies, Ophthalmology, Biology, Macular dystrophy, Macular scarring

The "US Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Wet Age-Related Macular Degeneration Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Wet Age-Related Macular Degeneration Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Wet Age-Related Macular Degeneration pipeline products, Wet Age-Related Macular Degeneration epidemiology, Wet Age-Related Macular Degeneration market valuations and forecast, Wet Age-Related Macular Degeneration drugs sales and competitive landscape in the US.
  • Wet Age-Related Macular Degeneration pipeline: Find out the products in clinical trials for the treatment of Wet Age-Related Macular Degeneration by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Wet Age-Related Macular Degeneration epidemiology: Find out the number of patients diagnosed (prevalence) with Wet Age-Related Macular Degeneration in the US
    Wet Age-Related Macular Degeneration drugs: Identify key products marketed and prescribed for Wet Age-Related Macular Degeneration in the US, including trade name, molecule name, and company
    Wet Age-Related Macular Degeneration drugs sales: Find out the sales revenues of Wet Age-Related Macular Degeneration drugs in the US
    Wet Age-Related Macular Degeneration market valuations: Find out the market size for Wet Age-Related Macular Degeneration drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Wet Age-Related Macular Degeneration drugs market share: Find out the market shares for key Wet Age-Related Macular Degeneration drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Wet Age-Related Macular Degeneration products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005713/en/

Global Psoriatic Arthritis Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Pharmaceutical, Health, Clinical trials, Medical specialties, Health, Medicine, Psoriasis, Autoimmune diseases, Rheumatology, Pharmaceutical industry, Monoclonal antibodies, Psoriatic arthritis, Arthritis, Clinical trial, National Psoriasis Foundation

The "Global Psoriatic Arthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Psoriatic Arthritis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Psoriatic Arthritis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Psoriatic Arthritis market.
  • It covers emerging therapies for Psoriatic Arthritis in active clinical development stages including early and late stage clinical trials.
  • The report provides Psoriatic Arthritis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Ankylosing Spondylitis Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Health, Clinical trials, Medical specialties, Medicine, Clinical medicine, Rheumatology, Ankylosing spondylitis, Arthritis, Monoclonal antibodies, Pharmaceutical industry, Clinical trial, Axial spondyloarthritis, Bimekizumab

The "Global Ankylosing Spondylitis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ankylosing Spondylitis Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Ankylosing Spondylitis Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Ankylosing Spondylitis market.
  • It covers emerging therapies for Ankylosing Spondylitis in active clinical development stages including early and late stage clinical trials.
  • The report provides Ankylosing Spondylitis pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Latest data on lecanemab to be presented at Alzheimer's Association International Conference (AAIC)

Retrieved on: 
Wednesday, July 21, 2021
Health sciences, Medical research, Drugs, Monoclonal antibodies, Clinical research, Drug discovery, Pharmaceutical industry, Design of experiments

STOCKHOLM, July 21, 2021 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will hold several presentations at the Alzheimer's Association International Conference (AAIC) to be held in Denver, Colorado and virtually from July 26 to 30, 2021. The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.

Key Points: 
  • Baseline Characteristics for Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab (BAN2401)
    This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety.
  • There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
  • Oskar Bosson, Vice President Communications and Investor Relations, BioArctic AB